ArokaGO
  • Community

Company

ArokaGO

Your trusted medical tourism platform. Connect with world-class healthcare providers in Thailand.

Apple StoreGoogle Play
FacebookInstagramYouTubeTikTokLinkedInRahu

For Patients

  • Dashboard
  • Search Providers
  • Login
  • Register as Patient
  • Book Appointment

For Providers

  • Dashboard
  • Appointments
  • Chat
  • Login
  • Join as Provider

Contact Us

  • Bangkok, Thailand
  • +66 65 829 4562
  • contact@arokago.com

Legal

  • Disclaimer
  • Privacy Policy
  • Review Policy
  • Advertising

© 2026 ArokaGO. All rights reserved.

Australia Launches World’s First Personalized mRNA Vaccine Trial to Treat Aggressive Childhood Brain Cancer
  1. /
  2. News
  3. /
  4. Global Health News
2 min read
|
March 4, 2026

Australia Launches World’s First Personalized mRNA Vaccine Trial to Treat Aggressive Childhood Brain Cancer

Sydney — Australia has launched the world’s first clinical trial of a personalized mRNA vaccine designed to treat children and adolescents with advanced or treatment-resistant brain tumors.

Share this news
T
The ArokaGO Reporter
Global Health News
T
The ArokaGO Reporter
Global Health News

Sydney — Australia has launched the world’s first clinical trial of a personalized mRNA vaccine designed to treat children and adolescents with advanced or treatment-resistant brain tumors.

 

The University of Queensland announced that the PaedNEO-VAX study, led by the university in collaboration with the South Australian Health and Medical Research Institute, will recruit patients from eight children’s hospitals across Australia. The trial aims to provide new hope for families facing the country’s deadliest childhood disease.

 

Jordan Hansford, clinical trial lead at the institute, said the study will enroll pediatric patients with aggressive brain tumors that have recurred or failed to respond to existing treatments. These include glioma and medulloblastoma, two of the most serious types of brain tumors in children.

 

The trial will be conducted in two phases. Phase 1 will focus on evaluating the vaccine’s safety, while Phase 2 will assess its effectiveness, including its impact on patient survival rates and quality of life.

 

Brandon Wainwright, scientific lead of the trial at the University of Queensland’s Frazer Institute, said personalized mRNA cancer vaccines have already shown promising results in treating rare and difficult-to-treat cancers in adults, including pancreatic cancer and melanoma.

 

Researchers explained that each vaccine will be uniquely designed for individual patients. By sequencing the genome of each child’s tumor and using advanced data analysis, scientists can identify cancer-specific markers and select vaccine targets tailored to that tumor.

 

The customized vaccines will be manufactured in Queensland by Southern RNA and delivered to participating trial sites. Each patient is expected to receive their personalized vaccine within about 10 weeks after enrollment in the trial.

 

The clinical trial is supported by 2.58 million Australian dollars (approximately US$1.7 million) in funding from the Australian federal government.

 

Source : Xinhua Thai News

T
The ArokaGO Reporter
Global Health News

Articles in this category are written by our editorial team to keep you informed about the latest healthcare and medical tourism news.

More News

Researchers Develop ‘Artificial Pancreas’ That May Help Diabetes Patients Avoid Daily Insulin Injections
Previous

Researchers Develop ‘Artificial Pancreas’ That May Help Diabetes Patients Avoid Daily Insulin Injections

March 4, 2026

WHO: Up to 40% of Cancer Cases Worldwide Are Preventable
Next

WHO: Up to 40% of Cancer Cases Worldwide Are Preventable

March 4, 2026